Navigation Links
Positive results in Phase 2 trial of treatment of C-difficile-associated diarrhea
Date:11/3/2008

Princeton, N.J. and Jamaica Plain, Mass., November 3, 2008 Medarex, Inc. (Nasdaq: MEDX) and The Massachusetts Biologic Laboratories (MBL) of the University of Massachusetts Medical School (UMMS) today announced that a Phase 2 trial of an anti-C. difficile antibody combination treatment in patients with C. difficile Associated Diarrhea (CDAD) successfully met its primary objective. The top-line results from the recently completed multi-center, randomized, double-blind, placebo-controlled Phase 2 trial indicated a statistically significant reduction in recurrences of CDAD when compared with placebo. In the study, 200 patients symptomatic with CDAD receiving standard of care antibiotics (metronidazole or vancomycin) were randomized to receive either intravenous placebo or intravenous administration of a combination of MDX-066 (CDA-1) and MDX-1388 (CDB-1), two fully human antibodies that neutralize C. difficile toxins A and B, respectively.

Consistent with the published literature, the recurrence rate in the placebo-treated group exceeded 20 percent for patients following successful treatment with standard of care antibiotics. In comparison with placebo, MDX-066/MDX-1388 treatment reduced recurrence rates by approximately 70 percent (p=0.0004 on the intent-to-treat population). The antibody combination treatment was generally safe and well-tolerated. Full results from this Phase 2 trial are planned to be presented at a future scientific meeting.

The incidence and mortality associated with CDAD has been increasing , with estimates of over 500,000 cases in the United States, and approximately 15,000 deaths caused or contributed by C. difficile. The emergence of a highly virulent epidemic strain that produces much higher levels of toxins A and B has also been associated with morbidity and mortality in younger, healthier, and non-hospitalized patients.

"We are delighted with these dramatic results. CDAD is a gr
'/>"/>

Contact: Michael Cohen
michael.cohen@umassmed.edu
508-868-4778
University of Massachusetts Medical School
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Oral rinses used for tracking HPV-positive head and neck cancers holds promise for cancer screening
2. Vaccine against HER2-positive breast cancer offers complete protection in lab
3. Dry Tortugas show positive trends: Protected area slowly rebounding
4. Men unaware of their cancer risk when female relatives test positive for BRCA mutation
5. HGS announces positive Phase 2 LymphoStat-B at ACR meeting
6. Positive results for airway bypass
7. First results from hospital trials testing
8. Communication Intelligence Corporation Reports Third Quarter 2008 Financial Results
9. Synaptics Reports Record Results for First Quarter of Fiscal 2009
10. Synaptics to Report First Quarter Results on October 23
11. Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/2/2015)... April 2, 2015 Fingerprint Cards ... sensor FPC1025 from the distributor World Peace Industrial Group ... Q2 2015 although the major part of the shipments ... be used by smartphone manufacturers in China ... included in the communicated revenue guidance of + 1 000 ...
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... Center researchers reveals how a well-known tumor suppressor gene may ... published online today in Oncogene , focus on the ... who have hereditary breast and/or ovarian cancers, according to senior ... of Human Science at the School of Nursing & Health ...
... dementia and while some risks are known, for example ... clear. New research published in BioMed Central,s open access ... hospitalization and treatment in the intensive care unit (ICU) ... such as delirium, or acute dialysis are all independently ...
... small-scale polar storms could make a big difference to climate ... Anglia and the University of Massachusetts. Difficult-to-forecast polar ... are missing in most climate models. Research published ... could paint a different picture of climate change in years ...
Cached Biology News:Study uncovers mechanism used by BRCA1 to suppress tumors 2Worries about dementia how hospitalization affects the elderly 2'Missing' polar weather systems could impact climate predictions 2
(Date:4/23/2015)... (PRWEB) April 23, 2015 ... refer to a series of genetic tests that ... fibrosis, Lou Gehrig's disease, Huntington's disease, and Alzheimer's ... the gene composition and interaction in diseased tissue/cells ... as well as the response to treatment, such ...
(Date:4/23/2015)... Proove Biosciences , a ... excited to announce the launch of Proove ... assesses 62 genetic variations to predict good versus ... prescribed non-opioid pain medications, namely ibuprofen (brand name ... name Xanax) and acetaminophen (brand name Tylenol). ...
(Date:4/23/2015)... CA (PRWEB) April 23, 2015 Delpor, ... today announced that the United States Patent and Trademark ... Company’s NANOPOR™ technology. US Pat. No. ... Delpor’s microfabricated drug delivery device for the ... proprietary NANOPOR™ technology for the sustained (zero-order) release of ...
(Date:4/22/2015)... Wilmington, Del. (PRWEB) April 22, 2015 ... acquire Taxon Biosciences, Inc., a leading microbiome discovery ... capabilities and unparalleled market access in both seed ... solutions for agriculture customers globally. , “In ... Health and Industrial Biosciences segments sold more than ...
Breaking Biology Technology:Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 2Proove Biosciences Launches World’s First Test to Predict Responders to Commonly Prescribed Non-Opioid Pain Medications 3Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 2Delpor, Inc. Announces the Issuance of 2 New US Patents Based on its Nanopore Technology which Enables the Sustained Release of Drugs from a Small Implant Device 3DuPont Acquires Taxon Biosciences, Inc. 2DuPont Acquires Taxon Biosciences, Inc. 3DuPont Acquires Taxon Biosciences, Inc. 4
... TELK ) reported a net loss of $13.6 million, or ... compared with a net loss of,$14.3 million, or $0.27 per ... loss for the second quarter ended June 30, 2008, includes,a ... reflected in interest and other income (expense)., For the ...
... NEW YORK, Aug. 11 Immtech Pharmaceuticals,Inc. (Amex: ... ended June,30, 2008., For the three months ended ... for the three months ended June 30, 2007. The ... testing,agreement. Loss from operations for the three months ended ...
... GSK anticipates delivery of at least half of ... Aug. 11 GlaxoSmithKline (NYSE:,GSK) today announced that ... and FLUARIX(R) [Influenza Virus Vaccine] to U.S. customers,for ... Drug Administration,s,(FDA) Center for Biologics Evaluation and Research ...
Cached Biology Technology:Telik Announces Financial Results For 2008 Second Quarter 2Telik Announces Financial Results For 2008 Second Quarter 3Telik Announces Financial Results For 2008 Second Quarter 4Immtech Reports Fiscal First Quarter 2009 Results 2Immtech Reports Fiscal First Quarter 2009 Results 3GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 2GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 3GSK Begins Shipments of Fluarix(R) and FluLaval(R) to U.S. Customers for 2008-2009 Influenza Season 4
... The lyophilization stabilizer is designed to ... and for long-term storage. There ... ingredients. It is a convenient ... 7.2, and is superior to other ...
... The CERTOMAT IS, a true benchtop incubator-shaker, has ... Having a footprint of 540 x 680 ... large incubation chamber (370 x 505 x 510mm). ... the CERTOMAT IS is ideal for shaking applications ...
... TC-3000 is one of the smallest thermal cyclers ... choice of either the 0.5ml (20 samples) or ... , Fast heating and cooling rate of ... and high performance Fast track programming with ...
... StabilZyme HRP Conjugate Stabilizer is an aqueous ... and other non-toxic stabilizing chemicals in a ... 6.7. This product contains a ... 20 ppm Proclin 300 (Rohm and Haas ...
Biology Products: